StockData
Sight Sciences, Inc. logo

Sight Sciences, Inc. (SGHT) stock

SGHTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30164% above fair value
$10.77+0.28 (+2.67%)

Close on Nov 18, 2026Market cap $593.30MP/E –Yield –

Earnings

Sight Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 3, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$24.90M
+25.1% on a year earlier
EPS, Q3 FY2026
-$0.12
-$0.16 a year earlier
Latest guidance
Raised
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Sight Sciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 3, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$24.90M+25.1%-$0.12Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$23.40M+19.4%-$0.08Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close$19.70M+12.6%-$0.24Release
Q4 FY2025ended Dec 31, 2025Mar 4, 2026after the close$20.40M+6.8%-$0.08Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$19.90M-1.5%-$0.16Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$19.60M-8.4%-$0.23Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$17.50M–-$0.28Release
Q4 FY2024ended Dec 31, 2024Mar 5, 2025after the close$19.10M+1.6%-$0.23Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$20.20M+1.0%–Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024after the close$21.40M-8.9%-$0.25Release
Q4 FY2023ended Dec 31, 2023Mar 7, 2024after the close$18.80M-8.3%-$0.22Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Sight Sciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
growthFY2026+4% – +7%+7% – +15%LoweredAug 5, 2026
revenueFY2026$92.00M – $93.00M$82.00M – $88.00MRaisedNov 4, 2026
revenue guidanceFY2026$88.00M – $92.00M$83.00M – $89.00MRaisedAug 5, 2026
adjusted operating expensesnon-GAAPFY2026$92.00M – $94.00M$93.00M – $96.00MLoweredNov 4, 2026
adjusted operating expensesnon-GAAPFY2026$92.00M – $94.00M$93.00M – $96.00MLoweredAug 5, 2026
adjusted operating expenses increasenon-GAAPFY2026+6% – +9%–NewMay 6, 2026
increase compared to 2025non-GAAPFY2026+5% – +7%–LoweredAug 5, 2026
Interventional Dry Eye segment revenueFY2026$6.00M – $8.00M–LoweredMay 6, 2026
Interventional Glaucoma segment revenueFY2026$77.00M – $81.00M–NewMay 6, 2026
Interventional Glaucoma segment revenue growthFY2026+2% – +7%–NewMay 6, 2026

Guidance vs results

The last range Sight Sciences gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$76.00M – $78.00M$77.40MΣ4QWithin range
Q4 FY2021Revenue$14.50M – $14.80M$14.70MWithin range

Guidance history

Every forecast Sight Sciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026adjusted operating expensesFY2026$92.00M – $94.00MLowered
Nov 4, 2026revenueFY2026$92.00M – $93.00MRaised
Aug 5, 2026increase compared to 2025FY2026+5% – +7%Lowered
Aug 5, 2026adjusted operating expensesFY2026$92.00M – $94.00MLowered
Aug 5, 2026revenue guidanceFY2026$88.00M – $92.00MRaised
Aug 5, 2026growthFY2026+4% – +7%Lowered
Aug 5, 2026year-over-year growthFY2026+14% – +19%Raised
Aug 5, 2026Interventional Dry Eye revenueFY2026$9.00M – $11.00MLowered
Aug 5, 2026Interventional Glaucoma revenueFY2026$79.00M – $81.00MLowered
May 6, 2026adjusted operating expenses increaseFY2026+6% – +9%New
May 6, 2026Interventional Glaucoma segment revenue growthFY2026+2% – +7%New
May 6, 2026adjusted operating expensesFY2026$93.00M – $96.00MNew
May 6, 2026Interventional Dry Eye segment revenueFY2026$6.00M – $8.00MLowered
May 6, 2026Interventional Glaucoma segment revenueFY2026$77.00M – $81.00MNew
May 6, 2026revenueFY2026$83.00M – $89.00MNew
May 6, 2026revenue growthFY2026+7% – +15%New
Mar 4, 2026adjusted operating expensesFY2026$93.00M – $96.00MNew
Mar 4, 2026revenueFY2026$82.00M – $88.00MNew
Nov 6, 2025adjusted operating expensesFY2025$90.00M – $92.00MNew
Nov 6, 2025revenueFY2025$76.00M – $78.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Sight Sciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Update
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Update
  15. Update

See a number that looks wrong?